Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

Inclusion criteria

• Male/Female aged 6-13 years of age
• Diagnosis of SAR/PAR, with symptoms within the past 3 months
• Positive skin test to inhalant allergen with negative saline control
• No previous use of intranasal inhaled, oral, IV or topical steroid use within past 6 months.
• If the subject has asthma, only mild intermittent (per NAPP) guidelines treated with PRN bronchodilator

Exclusion criteria

• screening height outside the 5th and 95th percentiles
• History of abnormal growth
• Any other chronic condition beside allergic rhinitis or mild intermittent asthma
• Subject who has insufficient allergic rhinitis symptoms to require daily therapy during the trial.
• Subject with a known hypersensitivity to any active ingredients or excipents in the study medications
• Subject with nasal candidiasis, acute or chronic sinusitis, significant nasal polyposis (impairs nasal breathing), or other gross anatomical deformity of the nose sufficient to impair nasal breathing (e.g., deviated septum)
• Subjects with a history of substance abuse, mental illness or retardation
• Subjects with a history or presence of glaucoma or posterior subcapsular cataract
• Subjects with nocturnal enuresis.
• Use of Theophylline, Intal/Tilade or leukotriene modifiers.